Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK ALK L1122V ALK L1196M ALK D1203N ALK G1269A |
Therapy | Ceritinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK L1122V ALK L1196M ALK D1203N ALK G1269A | lung adenocarcinoma | predicted - resistant | Ceritinib | Case Reports/Case Series | Actionable | In a clinical case study, ALK D1203N and L1122V were identified in post-progression biopsy in a patient with metastatic lung adenocarcinoma harboring EML4-ALK, ALK G1269A, and ALK L1196M, who previously achieved a partial response on Zykadia (ceritinib) treatment (PMID: 38961982). | 38961982 |
PubMed Id | Reference Title | Details |
---|---|---|
(38961982) | Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report. | Full reference... |